The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses precision medicine in the field of multiple myeloma (MM). Dr Raje covers the example of vemurafenib monotherapy for BRAF mutation postive MM patients, and discusses future plans to combine the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib. She also highlights the fluidity of the term precision medicine and what should be included within this definition. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
